$PSTV Reentry - took a position at .59
$PSTV - Biotech Reentry Rocket at $0.59! ????
Why It’s a Good Reentry: You entered PSTV at $0.59 , near support ($0.55) after a +405% spike from $0.35 to $1.77 (Mar 6, 2025, ). Recent 50.9M volume (Jul 24, ) and catalysts (Jul 23 $1.6M CPRIT grant, Aug 14–16 trial data, Aug 18 earnings) signal a 20–50% run. Low float (~25.42M, X post: 6) and X hype drive volatility.
Technicals ????:
Price Action: At $0.5893 (+20.26% pre-market, Jul 24,), down from $1.77 peak (Mar 6). 1-year range: $0.1634–$2.31. Consolidating in $0.49–$0.59 range.
Bottom Bounce: Support at $0.49 (overnight low, and $0.55 (short-term). 50.9M volume (Jul 24) vs. 13.37M avg. signals accumulation.
Bullish Breakout: Resistance at $0.70 (recent high) and $1.00 (post-spike level). Break $0.70 with >20M volume targets $0.71–$0.88 (20–49% from $0.59).
Squeeze: Bollinger Bands tightening post -66% drop from $1.77, price near lower band (~$0.50). Low BBW signals volatility pop
RSI (14): ~50 (estimated), neutral, with upside to 70.
MACD: Buy signal from 3-month MACD, neutral daily, bullish crossover possible above $0.70.
Volume: 50.9M (Jul 24 pre-market), >3x 10-day avg (~13M), strong buying pressure.
Likelihood: Bottom bounce at $0.55 confirmed by volume; breakout above $0.70 likely with catalysts.
Fundamentals:
Business: Clinical-stage biotech developing REYOBIQ™ (rhenium-186 obisbemeda) for CNS cancers (glioblastoma, leptomeningeal metastases) and CNSide diagnostic platform .
Market Cap: $19.60M (Web ID: 9), micro-cap, high risk/reward.
Financials: Q1 2025 revenue $1.06M (vs. $1.48M estimate), net loss -$17.40M, EPS -$1.19 (vs. -$0.25 estimate,. 2024 revenue $5.82M (+18.54% YoY), losses -$12.98M (-2.54% YoY, ). Cash $3.6M (Dec 2024), bolstered by $15M private placement (Mar 2025) and $1.6M CPRIT grant (Jul 23,: 7).
Risks: Nasdaq delisting risk (10-Q delay, Nov 2025 deadline). High volatility (55% weekly, beta 1.10,). Negative EPS and low cash.
Analysts: Strong Buy (3 analysts), 12-month target $10.83 (+1,837% from $0.5893). H.C. Wainwright cut target to $3 from $5.50 (Jun 27).
Catalyst:
July 23, 2025: $1.6M CPRIT grant advance for ReSPECT-LM trial and CNSide, up to $6M more expected in 2025. Drove +20.26% pre-market .
August 14–16, 2025: ReSPECT-LM Phase 1 final results and CNSide presentations at SNO/ASCO CNS Metastases Conference. Phase 1 showed 5/7 patients with >80% tumor reduction, 1-year survival .
August 18, 2025: Q2 earnings, potential volatility driver.
June 24, 2025: Restructured $15M financing, eliminating 1.5B share dilution, boosting shareholder confidence.
X Sentiment: Bullish, with $9–$20 targets . CPRIT funding, trial data, and low float fuel hype.
Reentry Rationale:
Why Reentry: Your $0.59 entry (100 shares) is near $0.55 support, post +405% spike (Mar 6, $0.35–$1.77). 50.9M volume (Jul 24) and August catalysts mirror prior run setup.
Setup: Bottom bounce at $0.55, breakout above $0.70 could hit $0.71–$0.88 (20–49% from $0.59). Prior volatility confirms swing potential.
Why Good: Low float (25.42M), high volume, non-dilutive funding ($1.6M), and trial data (Aug 14–16) align with your 20–50% goal.
Swing Trade Plan (100 Shares at $0.59):
Entry: $0.59
Stop-Loss: $0.53
Targets: $0.75
Why It Runs: $0.59 entry is near $0.55 support with 50.9M volume (Jul 24), signaling reentry strength. CPRIT funding ($1.6M, Jul 23), ReSPECT-LM data (Aug 14–16), and earnings (Aug 18) drive 20–49% potential to $0.71–$0.88. Low float and X hype add volatility for a quick swing.
Strengths: PSTV’s 50.9M volume, low float (25.42M), and catalysts (CPRIT, trial data, earnings) make it a screener standout. Prior +405% run confirms
$PSTV - Biotech Reentry Rocket at $0.59! ????
Why It’s a Good Reentry: You entered PSTV at $0.59 , near support ($0.55) after a +405% spike from $0.35 to $1.77 (Mar 6, 2025, ). Recent 50.9M volume (Jul 24, ) and catalysts (Jul 23 $1.6M CPRIT grant, Aug 14–16 trial data, Aug 18 earnings) signal a 20–50% run. Low float (~25.42M, X post: 6) and X hype drive volatility.
Technicals ????:
Price Action: At $0.5893 (+20.26% pre-market, Jul 24,), down from $1.77 peak (Mar 6). 1-year range: $0.1634–$2.31. Consolidating in $0.49–$0.59 range.
Bottom Bounce: Support at $0.49 (overnight low, and $0.55 (short-term). 50.9M volume (Jul 24) vs. 13.37M avg. signals accumulation.
Bullish Breakout: Resistance at $0.70 (recent high) and $1.00 (post-spike level). Break $0.70 with >20M volume targets $0.71–$0.88 (20–49% from $0.59).
Squeeze: Bollinger Bands tightening post -66% drop from $1.77, price near lower band (~$0.50). Low BBW signals volatility pop
RSI (14): ~50 (estimated), neutral, with upside to 70.
MACD: Buy signal from 3-month MACD, neutral daily, bullish crossover possible above $0.70.
Volume: 50.9M (Jul 24 pre-market), >3x 10-day avg (~13M), strong buying pressure.
Likelihood: Bottom bounce at $0.55 confirmed by volume; breakout above $0.70 likely with catalysts.
Fundamentals:
Business: Clinical-stage biotech developing REYOBIQ™ (rhenium-186 obisbemeda) for CNS cancers (glioblastoma, leptomeningeal metastases) and CNSide diagnostic platform .
Market Cap: $19.60M (Web ID: 9), micro-cap, high risk/reward.
Financials: Q1 2025 revenue $1.06M (vs. $1.48M estimate), net loss -$17.40M, EPS -$1.19 (vs. -$0.25 estimate,. 2024 revenue $5.82M (+18.54% YoY), losses -$12.98M (-2.54% YoY, ). Cash $3.6M (Dec 2024), bolstered by $15M private placement (Mar 2025) and $1.6M CPRIT grant (Jul 23,: 7).
Risks: Nasdaq delisting risk (10-Q delay, Nov 2025 deadline). High volatility (55% weekly, beta 1.10,). Negative EPS and low cash.
Analysts: Strong Buy (3 analysts), 12-month target $10.83 (+1,837% from $0.5893). H.C. Wainwright cut target to $3 from $5.50 (Jun 27).
Catalyst:
July 23, 2025: $1.6M CPRIT grant advance for ReSPECT-LM trial and CNSide, up to $6M more expected in 2025. Drove +20.26% pre-market .
August 14–16, 2025: ReSPECT-LM Phase 1 final results and CNSide presentations at SNO/ASCO CNS Metastases Conference. Phase 1 showed 5/7 patients with >80% tumor reduction, 1-year survival .
August 18, 2025: Q2 earnings, potential volatility driver.
June 24, 2025: Restructured $15M financing, eliminating 1.5B share dilution, boosting shareholder confidence.
X Sentiment: Bullish, with $9–$20 targets . CPRIT funding, trial data, and low float fuel hype.
Reentry Rationale:
Why Reentry: Your $0.59 entry (100 shares) is near $0.55 support, post +405% spike (Mar 6, $0.35–$1.77). 50.9M volume (Jul 24) and August catalysts mirror prior run setup.
Setup: Bottom bounce at $0.55, breakout above $0.70 could hit $0.71–$0.88 (20–49% from $0.59). Prior volatility confirms swing potential.
Why Good: Low float (25.42M), high volume, non-dilutive funding ($1.6M), and trial data (Aug 14–16) align with your 20–50% goal.
Swing Trade Plan (100 Shares at $0.59):
Entry: $0.59
Stop-Loss: $0.53
Targets: $0.75
Why It Runs: $0.59 entry is near $0.55 support with 50.9M volume (Jul 24), signaling reentry strength. CPRIT funding ($1.6M, Jul 23), ReSPECT-LM data (Aug 14–16), and earnings (Aug 18) drive 20–49% potential to $0.71–$0.88. Low float and X hype add volatility for a quick swing.
Strengths: PSTV’s 50.9M volume, low float (25.42M), and catalysts (CPRIT, trial data, earnings) make it a screener standout. Prior +405% run confirms
